CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.

Technol Cancer Res Treat · 2026 · PMC13276229 · PMID 42308169

Europe PMC DOI

hedged sentence

0.0460

closest p · 0.9× alpha

0.0460

boldest claim

The sentences

borderline significantp=0.046actually significant

Conventional clinical prognostic factors (ECOG performance status and IMDC risk score) were not significant (p>0.17), while race was a borderline significant demographic factor (p=0.046).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.